Advertisement

Fertility preservation in gynecologic cancers

  • Enes Taylan
    Correspondence
    Corresponding author at: Davis Research Building, Room 3090, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, 90048, CA, USA.
    Affiliations
    Women’s Cancer Program at Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Laboratory of Molecular Reproduction and Fertility Preservation, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
    Search for articles by this author
  • Kutluk Oktay
    Affiliations
    Laboratory of Molecular Reproduction and Fertility Preservation, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA

    Innovation Institute for Fertility Preservation and IVF, New York, NY, USA

    Ovarian Transplantation Program, NYU Winthrop Hospital, Mineola, NY, USA
    Search for articles by this author
Published:October 08, 2019DOI:https://doi.org/10.1016/j.ygyno.2019.09.012

      Highlights

      • Numerous effective fertility preservation options exist for women with gynecological malignancies.
      • Conservative surgery is feasible in reproductive age women with gynecologic cancer.
      • Embryo, oocyte and ovarian tissue freezing followed by autotransplantation are successful fertility preservation approaches.
      • Special ovarian stimulation protocols exist for women with hormone sensitive cancers or for emergent fertility preservation.

      Abstract

      An increasing number of women in modern societies are delaying childbearing beyond the age of 35, and gynecologic cancers affect a significant proportion of reproductive age women who wish to preserve fertility for a future chance of childbearing. As a result, providing treatment options for fertility preservation in women with gynecologic cancer has become a crucial component of cancer survivorship care. In this review article, we discussed the current knowledge on fertility-sparing surgical approaches, as well as assisted reproductive technologies that can be utilized to preserve reproductive potential in women with cervical, endometrial, and ovarian cancer. A brief section on fertility preservation in pediatric gynecologic malignancies is also provided.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Howlader N.
        • Noone A.M.
        • Krapcho M.
        • Miller D.
        • Brest A.
        • Yu M.
        • et al.
        SEER Cancer Statistics Review, 1975–2016.
        National Cancer Institute, 2018
        • Bhasin S.
        • Kerr C.
        • Oktay K.
        • Racowsky C.
        The implications of reproductive aging for the health, vitality and economic welfare of human societies.
        J. Clin. Endocrinol. Metab. 2019; https://doi.org/10.1210/jc.2019-00315
        • Oktay K.
        • Harvey B.E.
        • Partridge A.H.
        • Quinn G.P.
        • Reinecke J.
        • Taylor H.S.
        • et al.
        Fertility Preservation in Patients with Cancer: ASCO Clinical Practice Guideline Update.
        J. Clin. Oncol. 2018; 36: 1994-2001
        • Ethics Committee of the American Society for Reproductive Medicine
        Electronic address Aao. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion.
        Fertil. Steril. 2018; 110: 380-386
        • Bedoschi G.
        • Navarro P.A.
        • Oktay K.
        Chemotherapy-induced damage to ovary: mechanisms and clinical impact.
        Future Oncol. 2016; 12: 2333-2344
        • Soleimani R.
        • Heytens E.
        • Darzynkiewicz Z.
        • Oktay K.
        Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise.
        Aging (Albany NY). 2011; 3: 782-793
        • Wallace W.H.
        • Thomson A.B.
        • Saran F.
        • Kelsey T.W.
        Predicting age of ovarian failure after radiation to a field that includes the ovaries.
        Int. J. Radiat. Oncol. Biol. Phys. 2005; 62: 738-744
        • Wo J.Y.
        • Viswanathan A.N.
        Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients.
        Int. J. Radiat. Oncol. Biol. Phys. 2009; 73: 1304-1312
        • Taylan E.
        • Oktay K.H.
        Current state and controversies in fertility preservation in women with breast cancer.
        World J Clin Oncol. 2017; 8: 241-248
        • Roy R.
        • Chun J.
        • Powell S.N.
        BRCA1 and BRCA2: different roles in a common pathway of genome protection.
        Nat. Rev. Cancer. 2011; 12: 68-78
        • Titus S.
        • Li F.
        • Stobezki R.
        • Akula K.
        • Unsal E.
        • Jeong K.
        • et al.
        Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans.
        Sci. Transl. Med. 2013; 5: 172ra21
        • Lin W.
        • Titus S.
        • Moy F.
        • Ginsburg E.S.
        • Oktay K.
        Ovarian aging in women with BRCA germline mutations.
        J. Clin. Endocrinol. Metab. 2017; 102: 3839-3847
        • Oktay K.
        • Kim J.Y.
        • Barad D.
        • Babayev S.N.
        Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
        J. Clin. Oncol. 2010; 28: 240-244
        • Lin W.T.
        • Beattie M.
        • Chen L.M.
        • Oktay K.
        • Crawford S.L.
        • Gold E.B.
        • et al.
        Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California.
        Cancer. 2013; 119: 1652-1659
        • Phillips K.A.
        • Collins I.M.
        • Milne R.L.
        • McLachlan S.A.
        • Friedlander M.
        • Hickey M.
        • et al.
        Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
        Hum. Reprod. 2016; 31: 1126-1132
        • Johnson L.
        • Sammel M.D.
        • Domchek S.
        • Schanne A.
        • Prewitt M.
        • Gracia C.
        Antimullerian hormone levels are lower in BRCA2 mutation carriers.
        Fertil. Steril. 2017; 107 (e6): 1256-1265
        • Quinn G.P.
        • Vadaparampil S.T.
        • Lee J.H.
        • Jacobsen P.B.
        • Bepler G.
        • Lancaster J.
        • et al.
        Physician referral for fertility preservation in oncology patients: a national study of practice behaviors.
        J. Clin. Oncol. 2009; 27: 5952-5957
        • Selter J.
        • Huang Y.
        • Grossman Becht L.C.
        • Palmerola K.L.
        • Williams S.Z.
        • Forman E.
        • et al.
        Use of fertility preservation services in female reproductive-aged cancer patients.
        Am. J. Obstet. Gynecol. 2019; https://doi.org/10.1016/j.ajog.2019.05.009
        • Deshpande N.A.
        • Braun I.M.
        • Meyer F.L.
        Impact of fertility preservation counseling and treatment on psychological outcomes among women with cancer: a systematic review.
        Cancer. 2015; 121: 3938-3947
        • Taylan E.
        • Oktay K.
        Autologous transplantation of human ovarian tissue.
        in: Leung P. Adashi E. The Ovary. 3 ed. Elsevier, 2019: 493-500
        • Oktay K.
        • Taylan E.
        • Kawahara T.
        • Cillo G.M.
        Robot-assisted orthotopic and heterotopic ovarian tissue transplantation techniques: surgical advances since our first success in 2000.
        Fertil. Steril. 2019; 111: 604-606
        • Oktay K.
        • Taylan E.
        • Sugishita Y.
        • Goldberg G.M.
        Robot-assisted laparoscopic transplantation of frozen-thawed ovarian tissue.
        J. Minim. Invasive Gynecol. 2017; 24: 897-898
        • Lee S.
        • Ozkavukcu S.
        • Heytens E.
        • Moy F.
        • Oktay K.
        Value of early referral to fertility preservation in young women with breast cancer.
        J. Clin. Oncol. 2010; 28: 4683-4686
        • Horicks F.
        • Van Den Steen G.
        • Gervy C.
        • Clarke H.J.
        • Demeestere I.
        Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice.
        Mol. Hum. Reprod. 2018; 24: 221-232
        • Moore H.C.
        • Unger J.M.
        • Phillips K.A.
        • Boyle F.
        • Hitre E.
        • Porter D.
        • et al.
        Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
        N. Engl. J. Med. 2015; 372: 923-932
        • Oktay K.
        • Rodriguez-Wallberg K.
        • Munster P.
        Ovarian protection during adjuvant chemotherapy.
        N. Engl. J. Med. 2015; 372: 2268-2269
        • Oktay K.
        • Taylan E.
        • Rodriguez-Wallberg K.A.
        • Bedoschi G.
        • Turan V.
        • Pacheco F.
        Goserelin does not preserve ovarian function against chemotherapy-induced damage.
        Ann. Oncol. 2018; 29: 512-513
        • Demeestere I.
        • Brice P.
        • Peccatori F.A.
        • Kentos A.
        • Dupuis J.
        • Zachee P.
        • et al.
        No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial.
        J. Clin. Oncol. 2016; 34: 2568-2574
        • Munster P.N.
        • Moore A.P.
        • Ismail-Khan R.
        • Cox C.E.
        • Lacevic M.
        • Gross-King M.
        • et al.
        Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
        J. Clin. Oncol. 2012; 30: 533-538
        • Kyrgiou M.
        • Koliopoulos G.
        • Martin-Hirsch P.
        • Arbyn M.
        • Prendiville W.
        • Paraskevaidis E.
        Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis.
        Lancet. 2006; 367: 489-498
        • Wright J.D.
        • NathavithArana R.
        • Lewin S.N.
        • Sun X.
        • Deutsch I.
        • Burke W.M.
        • et al.
        Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access.
        Obstet. Gynecol. 2010; 115: 585-590
      1. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer (Version 4.2019).

        • Bogani G.
        • Chiappa V.
        • Vinti D.
        • Somigliana E.
        • Filippi F.
        • Murru G.
        • et al.
        Long-term results of fertility-sparing treatment for early-stage cervical cancer.
        Gynecol. Oncol. 2019 Jul; 154: 89-94
        • Prodromidou A.
        • Iavazzo C.
        • Fotiou A.
        • Psomiadou V.
        • Douligeris A.
        • Vorgias G.
        • et al.
        Short- and long term outcomes after abdominal radical trachelectomy versus radical hysterectomy for early stage cervical cancer: a systematic review of the literature and meta-analysis.
        Arch. Gynecol. Obstet. 2019 Jul; 300: 25-31
        • Cao D.Y.
        • Yang J.X.
        • Wu X.H.
        • Chen Y.L.
        • Li L.
        • Liu K.J.
        • et al.
        Comparisons of vaginal and abdominal radical trachelectomy for early-stage cervical cancer: preliminary results of a multi-center research in China.
        Br. J. Cancer. 2013; 109: 2778-2782
        • Bentivegna E.
        • Gouy S.
        • Maulard A.
        • Chargari C.
        • Leary A.
        • Morice P.
        Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.
        Lancet Oncol. 2016; 17: e240-e253
        • Moawad N.S.
        • Santamaria E.
        • Rhoton-Vlasak A.
        • Lightsey J.L.
        Laparoscopic ovarian transposition before pelvic cancer treatment: ovarian function and fertility preservation.
        J. Minim. Invasive Gynecol. 2017; 24: 28-35
        • Baiocchi G.
        • Mantoan H.
        • Chen M.J.
        • Faloppa C.C.
        Uterine transposition after radical trachelectomy.
        Gynecol. Oncol. 2018; 150: 387-388
        • Ghadjar P.
        • Budach V.
        • Kohler C.
        • Jantke A.
        • Marnitz S.
        Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation.
        Radiat. Oncol. 2015; 10: 50
        • Koh W.J.
        • Greer B.E.
        • Abu-Rustum N.R.
        • Apte S.M.
        • Campos S.M.
        • Chan J.
        • et al.
        Uterine neoplasms, version 1.2014.
        J. Natl. Compr. Cancer Netw. 2014; 12: 248-280
        • Rodolakis A.
        • Biliatis I.
        • Morice P.
        • Reed N.
        • Mangler M.
        • Kesic V.
        • et al.
        European Society of Gynecological Oncology Task Force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients.
        Int. J. Gynecol. Cancer. 2015; 25: 1258-1265
        • Greenwald Z.R.
        • Huang L.N.
        • Wissing M.D.
        • Franco E.L.
        • Gotlieb W.H.
        Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?.
        Cancer. 2017; 123: 1545-1554
        • Gunderson C.C.
        • Fader A.N.
        • Carson K.A.
        • Bristow R.E.
        Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
        Gynecol. Oncol. 2012; 125: 477-482
        • Corzo C.
        • Barrientos Santillan N.
        • Westin S.N.
        • Ramirez P.T.
        Updates on conservative management of endometrial cancer.
        J. Minim. Invasive Gynecol. 2018; 25: 308-313
        • Mazzon I.
        • Corrado G.
        • Masciullo V.
        • Morricone D.
        • Ferrandina G.
        • Scambia G.
        Conservative surgical management of stage IA endometrial carcinoma for fertility preservation.
        Fertil. Steril. 2010; 93: 1286-1289
        • Jia P.
        • Zhang Y.
        Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer.
        Oncotarget. 2017; 8: 59940-59949
        • Testa G.
        • McKenna G.J.
        • Gunby Jr., R.T.
        • Anthony T.
        • Koon E.C.
        • Warren A.M.
        • et al.
        First live birth after uterus transplantation in the United States.
        Am. J. Transplant. 2018; 18: 1270-1274
        • Palomba S.
        • Falbo A.
        • Del Negro S.
        • Rocca M.
        • Russo T.
        • Cariati F.
        • et al.
        Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up.
        Hum. Reprod. 2010; 25: 1966-1972
        • Darai E.
        • Fauvet R.
        • Uzan C.
        • Gouy S.
        • Duvillard P.
        • Morice P.
        Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options.
        Hum. Reprod. Update. 2013; 19: 151-166
        • Ditto A.
        • Martinelli F.
        • Bogani G.
        • Lorusso D.
        • Carcangiu M.
        • Chiappa V.
        • et al.
        Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures.
        Gynecol. Oncol. 2015; 138: 78-82
        • Zapardiel I.
        • Diestro M.D.
        • Aletti G.
        Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes.
        Eur. J. Surg. Oncol. 2014; 40: 387-393
        • Oktay K.
        • Buyuk E.
        • Libertella N.
        • Akar M.
        • Rosenwaks Z.
        Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
        J. Clin. Oncol. 2005; 23: 4347-4353
        • Azim A.
        • Oktay K.
        Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma.
        Fertil. Steril. 2007; 88: 657-664
        • Azim A.A.
        • Costantini-Ferrando M.
        • Oktay K.
        Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
        J. Clin. Oncol. 2008; 26: 2630-2635
        • Sonmezer M.
        • Turkcuoglu I.
        • Coskun U.
        • Oktay K.
        Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles.
        Fertil Steril. 2011; 95: 2125 e9-2125 e11
        • Oktay K.
        • Karlikaya G.
        Ovarian function after transplantation of frozen, banked autologous ovarian tissue.
        N. Engl. J. Med. 2000; 342: 1919
        • Oktay K.
        • Buyuk E.
        • Veeck L.
        • Zaninovic N.
        • Xu K.
        • Takeuchi T.
        • et al.
        Embryo development after heterotopic transplantation of cryopreserved ovarian tissue.
        Lancet. 2004; 363: 837-840
        • Oktay K.
        • Bedoschi G.
        • Pacheco F.
        • Turan V.
        • Emirdar V.
        First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix scaffold using robot-assisted minimally invasive surgery.
        Am. J. Obstet. Gynecol. 2016; 214: 94 e1-9
        • Taylan E.
        • Oktay K.
        Application of decellularized tissue scaffolds in ovarian tissue transplantation.
        Methods Mol. Biol. 2018; 1577: 177-181
        • Pacheco F.
        • Oktay K.
        Current success and efficiency of autologous ovarian transplantation: a meta-analysis.
        Reprod. Sci. 2017; 24: 1111-1120
        • Sanchez-Serrano M.
        • Novella-Maestre E.
        • Rosello-Sastre E.
        • Camarasa N.
        • Teruel J.
        • Pellicer A.
        Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation.
        Hum. Reprod. 2009; 24: 2238-2243
        • Dolmans M.M.
        • Iwahara Y.
        • Donnez J.
        • Soares M.
        • Vaerman J.L.
        • Amorim C.A.
        • et al.
        Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients.
        Hum. Reprod. 2016; 31: 2292-2302
        • Park J.Y.
        • Kim D.Y.
        • Suh D.S.
        • Kim J.H.
        • Kim Y.M.
        • Kim Y.T.
        • et al.
        Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.
        Gynecol. Oncol. 2015; 137: 418-422
        • Andrassy R.J.
        • Wiener E.S.
        • Raney R.B.
        • Hays D.M.
        • Arndt C.A.
        • Lobe T.E.
        • et al.
        Progress in the surgical management of vaginal rhabdomyosarcoma: a 25-year review from the Intergroup Rhabdomyosarcoma Study Group.
        J. Pediatr. Surg. 1999; 34 (discussion 4-5): 731-734
        • Azim Jr., H.A.
        • Kroman N.
        • Paesmans M.
        • Gelber S.
        • Rotmensz N.
        • Ameye L.
        • et al.
        Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.
        J. Clin. Oncol. 2013; 31: 73-79
        • Li F.
        • Turan V.
        • Lierman S.
        • Cuvelier C.
        • De Sutter P.
        • Oktay K.
        Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death.
        Hum. Reprod. 2014; 29: 107-113
        • White Y.A.
        • Woods D.C.
        • Takai Y.
        • Ishihara O.
        • Seki H.
        • Tilly J.L.
        Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women.
        Nat. Med. 2012; 18: 413-421
        • Yamashiro C.
        • Sasaki K.
        • Yabuta Y.
        • Kojima Y.
        • Nakamura T.
        • Okamoto I.
        • et al.
        Generation of human oogonia from induced pluripotent stem cells in vitro.
        Science. 2018; 362: 356-360
        • Telfer E.E.
        Future developments: in vitro growth (IVG) of human ovarian follicles.
        Acta Obstet. Gynecol. Scand. 2019; 98: 653-658
        • Dolmans M.M.
        • Amorim C.A.
        Construction and use of artificial ovaries.
        Reproduction. 2019; https://doi.org/10.1530/REP-18-0536